Sign in
Taking people in United StatesNo phase

How Inflammation in Type 2 Diabetes, Kidney Failure and Irritable Bowel Disease Affects Drugs

Measures inflammation in people with these illnesses to estimate how it changes drug levels.

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the site
Trial code
Registry title
Drug Interaction Potential of Pro-Inflammatory Conditions
Status
Recruiting
People taking part
150 people, planned
Started
1 Nov 2025
Expected to end
31 Dec 2030
Type of study
Observational, 3 groups
Treatments tested
  • None (Observational)
Record updated
22 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults and children with type 2 diabetes, inflammatory bowel disease or end stage kidney disease. It studies how inflammation changes the way the body handles drugs.

Age
12 Years to 99 Years
Sex
All sexes can join.
Disease stage
A diagnosis of a pro-inflammatory disease: T2DM, IBD or ESRD. People with different severities of these diseases are studied.
Earlier treatment
People currently on systemic immunosuppressant drugs cannot join.

Main reasons for not taking part

  • Another autoimmune disorder (not IBD), such as lupus, Sjogren's syndrome, multiple sclerosis, type 1 diabetes, Behcet's disease or ankylosing spondylitis
  • An infection that currently needs medical treatment
  • Treatment with systemic immunosuppressant drugs at the same time
  • Not able to give written informed consent and HIPAA authorization

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Diagnosed with a pro-inflammatory disease, including T2DM, IBD, and ESRD
  • Ability to provide written informed consent and HIPAA authorization

Who cannot take part

  • Concomitant treatment with systemic immunosuppressant drugs
  • Diagnosis or past medical history of non-IBD autoimmune disorder, including systemic lupus erythematosus, Sjogren's syndrome, multiple sclerosis, type 1 diabetes mellitus, Behcet's disease, and ankylosing spondylitis
  • Current infection requiring medical treatment (note: if a prospective patient's infection resolves, they can be re-screened for trial inclusion)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 99 years old?

Where in United States

  • Indiana University HospitalIndianapolis, United StatesContact: Ross RobinsonTaking people

About the trial

What the trial wants to find out

Pro-inflammatory cytokines, which are elevated in pro-inflammatory disease states (e.g., type II diabetes mellitus [T2DM], irritable bowel diseases [IBD], and end stage renal disease [ESRD]) have been shown to inhibit hepatic drug-metabolizing enzymes, including members of the cytochrome P450 (CYP) family, and drug transporters; resultantly, pro-inflammatory diseases have been demonstrated to increase the exposure and potential for adverse drug events with co-administered CYP and drug transporter substrates. However, the clinical relevance of pro-inflammatory disease-drug interactions has not been systematically evaluated. The long-term goal of this research is to establish clinical strategies to mitigate pro-inflammatory disease-drug interactions and associated adverse drug events. The specific objective of this study is to determine the clinical relevance of pro-inflammatory disease-drug interactions, including establishment of the effect of pro-inflammatory diseases on drug disposition throughout disease trajectories (i.e., determining the differential effects on drug disposition based on the severity of disease). Towards this objective, this study will investigate the extent of increases in inflammation in patients with varying severities of pro-inflammatory diseases and estimate the resulting effects on drug disposition. Cytokine/chemokine concentrations and immune cell profiles will be assayed from blood samples of adult and pediatric patients with differing severities of pro-inflammatory diseases, using established disease monitoring parameters (e.g., glycosylated hemoglobin [HbA1C] for T2DM, C-reactive protein [CRP] for IBD, proteinuria for ESRD). The effect of changes in inflammation during differing severities of these pro-inflammatory diseases on drug disposition will then be estimated using established pharmacokinetic modeling approaches (e.g., physiologically-based pharmacokinetic modeling [PBPK]).

The 3 groups in the trial

  • Type 2 Diabetes Mellitus

    Treatment: None (Observational)

  • End Stage Renal Disease

    Treatment: None (Observational)

  • Irritable Bowel Syndrome

    Treatment: None (Observational)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Drug Interaction Potential of Pro-Inflammatory Conditions
Plain-language title
How Inflammation in Type 2 Diabetes, Kidney Failure and Irritable Bowel Disease Affects DrugsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07360938, who can take part
Record updated
22 January 2026